DEVICE GUIDE > Drug-Coated Balloons

Company Name Product Name Drug Type Drug Concentration (µg/mm2) Excipient Type Wire Compatibility (inch) Shaft Length (cm) Sheath Sizing Size (F) Balloon Diameters (mm) Balloon Lengths (mm) US FDA Indicated Use
Bard Peripheral Vascular, Inc. Lutonix 035 (AV indication) Paclitaxel 2 Polysorbate, sorbitol 0.035 40, 75, 100 5–9 4–12 40, 60, 80, 100 Indicated for percutaneous transluminal angioplasty, after predilatation, for treatment of stenotic lesions of dysfunctional native arteriovenous dialysis fistulas that are 4–12 mm in diameter and up to 80 mm in length
Bard Peripheral Vascular, Inc. Lutonix 035 (SFA/popliteal indication) Paclitaxel 2 Polysorbate, sorbitol 0.035 75, 130 5 (all sizes) 4–7 40, 60, 80, 100, 120, 150 Indicated for percutaneous transluminal angioplasty, after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions up to 300 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4–7 mm
Medtronic In.Pact Admiral Paclitaxel 3.5 Urea 0.035 80, 130 5 (4 mm), 6 (5, 6 mm), 7 (7 mm) 4–7 40, 60, 80, 120, 150 Indicated for PTA, after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions with lengths up to 180 mm in superficial femoral or popliteal arteries with reference vessel diameters of 4–7 mm
Spectranetics, a Philips company Stellarex Paclitaxel 2 Polyethylene glycol (PEG) 0.035 80, 135 6 4, 5, 6 40, 60, 80, 120 De novo and restenotic lesions in the superficial femoral or popliteal arteries

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.